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The Malaria Policy Advisory Committee to the World Health Organization met for the first time from 31 January to 2
February 2012 in Geneva, Switzerland. This article provides a summary of the discussions, conclusions and
recommendations from that meeting, as part of the newly launched Malaria Journal thematic series “WHO Malaria
Policy Advisory Committee: Reports and Recommendations”.
Summaries are provided, referencing the relevant background documents, for the meeting sessions on global
malaria control, drug resistance and containment, rapid diagnostic test procurement criteria, larviciding, classification
of countries for elimination, estimating malaria cases and deaths, and seasonal malaria chemoprevention. Policy
statements, position statements, and guidelines that will arise from the MPAC meeting conclusions and
recommendations will be formally issued and disseminated to World Health Organization member states by the
World Health Organization Global Malaria Programme.
Keywords: Global, Malaria, Policy development, WHO, Drug resistance, Diagnostic tests, Mosquito control,
Elimination, Surveillance, ChemopreventionBackground
The Malaria Policy Advisory Committee [1] (MPAC) to the
WHO met for the first time from 31 January to 2 February
2012 in Geneva, Switzerland [2]. This article provides a
summary of the discussions, conclusions and recommenda-
tions from that meeting a as part of the newly launched
Malaria Journal thematic series “WHO Malaria Policy Ad-
visory Committee: Reports and Recommendations”, the
prelude for which was published earlier [3].
The following sections of this article provide details and
references for the background documents presented at the
open sessions of the meeting on global malaria control,
drug resistance and containment, rapid diagnostic test
(RDT) procurement criteria, larviciding, classification of
countries for elimination, estimating malaria cases and
deaths, and seasonal malaria chemoprevention (SMC). The
MPAC discussion and recommendations related to these
topics, which took place partially in closed session, are also
included. MPAC decisions are reached by consensus [3].Correspondence: newmanr@who.int
Global Malaria Programme, World Health Organization, 20 Avenue Appia,
CH-1211, Geneva 27, Switzerland
© 2012 WHO; licensee BioMed Central Ltd. Th
Attribution License (http://creativecommons.org
any medium, provided the original work is propReport from the WHO global malaria programme
The Director of the WHO Global Malaria Programme
(WHO-GMP) opened the meeting with an overview of
progress in global malaria control and elimination as
reported in the World Malaria Report 2011 [4,5], includ-
ing a summary of the opportunities and major challenges
ahead, such as sustaining political commitment, man-
aging the projected decrease in programme funding, and
increasing anti-malarial drug and insecticide resistance.
Action by WHO-GMP, MPAC, and the global malaria
community as a whole, will be critical in addressing
these challenges.
The MPAC commended the increasing quality of each
issue of the annual World Malaria Report, and strongly
encouraged the continued commitment and participation
of WHO member states in providing quality data to
WHO-GMP to aid the accurate monitoring of progress
against global malaria goals. They recommended
strengthened linkage of the World Malaria Report to the
African Leaders Malaria Alliance (ALMA) score card [6]
to increase the feedback loop and engagement with
WHO member states. The MPAC also highlighted theis is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
erly cited.
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that addresses local transmission factors, as opposed to a
narrow focus on procurement of commodities, especially
now that transmission is decreasing in many parts of the
world [4].Drug resistance and containment
WHO-GMP presented an update on artemisinin resistance
[7] in known foci in Cambodia and Thailand, and new sus-
pected foci of resistance in Myanmar and Viet Nam, as
well as a proposal for the establishment of a standing
Technical Expert Group (TEG) to advise the MPAC spe-
cifically on drug resistance and containment and the im-
plementation of the Global Plan for Artemisinin
Resistance Containment (GPARC) [8]. The rationale for
convening a standing TEG for this purpose is that the
issue of anti-malarial drug resistance will need to be
addressed with continued urgency, and that the topic is
too large to fall within the remit of the existing TEG on
chemotherapy or a new short-term Evidence Review
Group (ERG).
The MPAC recommended that the scope of the TEG
should cover broad aspects of drug resistance and con-
tainment, but that the draft terms of reference (ToR)
appeared to focus heavily on confirmation of artemisinin
resistance and monitoring. They advised that the scope
of the TEG, and its membership, be broadened to reflect
these needs, and to cover all regions, not just Asia. They
also recommended that the proposed TEG on drug re-
sistance and containment and the current standing TEG
on chemotherapy should meet back-to-back, with an
overlapping session when possible, as their areas of work
are closely related. Each TEG’s recommendations will
have an impact on those of the other TEG, which requires
that their work be well co-ordinated.
The TEG will identify priorities for operational re-
search. Initial priorities identified by MPAC members
included the use of primaquine as a gametocytocide in
the treatment for Plasmodium falciparum and the identi-
fication of molecular markers of artemisinin resistance.
The MPAC highlighted the issue of funding for and
implementation of drug efficacy monitoring systems and
suggested making better use of potential funding from
the Global Fund for AIDS, Tuberculosis and Malaria
(Global Fund) as a point of leverage, and that therapeutic
efficacy monitoring could be required for grants that
procured anti-malarial medicines. The Global Fund, a
standing observer to the MPAC, raised the issue that
making surveillance a key performance indicator had
implications, namely it might result in withholding fund-
ing to countries where monitoring requirements are not
adequately met, which would be at odds with the push
to have anti-malarial medicines listed as life-savingcommodities on a par with antiretroviral therapy. These
are issues for the new TEG to consider.
The MPAC recommended that WHO-GMP should
lead the global artemisinin resistance containment effort,
and unanimously endorsed the creation of a TEG to pro-
vide on-going advice to the MPAC in how best to sup-
port the implementation of the GPARC.
The TEG ToR were reformulated in accordance with
MPAC suggestions for improvement and presented back
to MPAC before the end of the meeting; they were
approved [9] pending minor corrections. WHO-GMP, in
close consultation with the MPAC, will convene the TEG
prior to the next MPAC meeting to conduct a critical re-
view of global drug resistance monitoring.Rapid diagnostic test procurement criteria
WHO-GMP presented arguments for and against chan-
ging the WHO recommended RDT procurement criteria
based on the WHO Malaria RDT Product Testing
Programme b from a minimum threshold panel detection
score (PDS) of 50%, set in 2009, to 75% for P. falciparum
at low parasite densities (200 parasites/μL) in areas with
high malaria transmission [10]. Of note, the PDS is a
measure of product performance that is not the same as
the sensitivity of the test in clinical settings c.
The main arguments in favour of changing the thresh-
old were that: (a) it will simplify procurement by aligning
the detection thresholds used for both P. falciparum and
Plasmodium vivax in all transmission settings; (b) a new
threshold of 75% will be met by 21, as opposed to 24, P.
falciparum-only RDTs, resulting in little change in terms
of current product availability based on results of Rounds
1–3; (c) as malaria control improves, demand will in-
crease for RDTs with PDS of at least 75% at low parasite
densities for P. falciparum and P. vivax; and (d) there
are immediate, theoretical benefits to individuals if a new
threshold of 75% is implemented, particularly for vulner-
able groups, such as asymptomatic pregnant women.
The main arguments against changing the threshold
were that: (a) based on several recent studies in moderate
to high transmission settings, there is no evidence that a
PDS threshold of 50% for P. falciparum at low parasite
densities (200 parasites/μL) is unsafe for patients; (b) the
linear distribution of PDS, with small incremental differ-
ences and lack of confidence intervals, means that setting
threshold levels could be perceived as arbitrary; and (c) as
WHO-GMP does not systematically monitor which RDTs
are currently in use in endemic countries and as Round 4
of the WHO Malaria RDT Product Testing is on-going, it
is not known how changes in the threshold will impact
existing practices and how many additional RDTs will be
excluded from procurement based on the proposed change
in threshold level.
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sized that a change in current criteria must be accompan-
ied by assessment of the risk-benefits associated with
maintaining the current criteria as compared to the public
health risk-benefits if performance standards are raised.
The MPAC reviewed the need for the rigorous require-
ments of inter-test and inter-lot consistency, the statistical
basis of repeated tests for a given number of samples from
wild type parasites, the relation between PDS threshold
and RDT sensitivity in well-conducted field studies, and
the relevance of other important parameters such as sta-
bility at high temperature. However, they concluded that
it was important that testing of RDTs against an inde-
pendent panel of parasite-derived antigens be robust and
mandatory, and that setting a diagnostic performance
threshold measure was useful for national malaria control
programmes (NMCP) as well as manufacturers, in order
to encourage the development and deployment of better
performing tests.
Also noted was that the fact that the majority of RDTs
currently in use meet the proposed threshold of 75%
PDS, so there is little likelihood that this will generate an
increase in costs of the diagnostic tests. However, there
is potential for increased costs at the country level to
cover such activities as health care worker training and
communication if the new recommendations result in a
new RDT being procured.
Following discussion, the MPAC recommended a PDS
threshold of 75% for P. falciparum at low parasite densities
(200 parasites/μL) in areas of high transmission. The
MPAC recommended calling on industry and development
partners to make RDTs specifically for low transmission
settings, and for the detection of low parasite densities in
asymptomatic carriers with good stability at high tempera-
tures in the field, congruent with the call made by the Mal-
ERA (Malaria Eradication Research Agenda) Consultative
Group on Diagnoses and Diagnostics [11].
The MPAC recommended that WHO-GMP promotes
the use of the on-line interactive RDT guide [12], devel-
oped by the Foundation for Innovative New Diagnostics
(FIND), which allows buyers to select RDTs based on
multiple factors such as target species, diagnostic per-
formance, and stability at high temperatures, so that the
RDT chosen is the one most suitable for their intended
areas of use.
Larviciding
WHO-GMP presented a draft position statement entitled:
The role of larviciding for malaria control, with particular
reference to Africa [13] prompted by a longstanding need
for updated guidance on this issue, as well as current plans
in several African countries for a substantial expansion of
larviciding activities. The paper was developed by WHO-
GMP in mid 2011, and then shared with nearly 100experts, of whom approximately half responded. The ex-
pert opinions gathered during this consultative phase were
instrumental in improving the original draft.
The MPAC noted the low volume of high quality and
generalizable data with regard to larviciding, and that
most vector control experts agree there are some specific
circumstances where larviciding programmes can be ef-
fective and useful for malaria control (breeding sites are
few, fixed and findable), but that the likely impact of this
intervention may not represent a good use of limited
resources and cannot substitute for indoor residual
spraying (IRS) or long-lasting insecticide-treated nets
(LLINs) in most settings, especially in rural areas. They
agreed that for malaria vector control in Africa, it is im-
portant that NMCP managers can distinguish between
situations where larviciding is likely to be useful (e.g. in
selected urban settings), and those where it is inappro-
priate (e.g. in the majority of rural African settings). This
view was supported by the two African NMCP represen-
tatives who had been invited to participate in the MPAC
meeting as per its ToR [1].
The MPAC noted the recent resurgence of interest in
larviciding in certain African countries. MPAC also
recognized that research gaps exist and that it may be
some time before there is sufficient evidence for a com-
prehensive policy statement on larval source manage-
ment (LSM). Therefore, MPAC agreed that there is an
urgent need for an interim position statement on the use
of larviciding in Africa [14]. The MPAC recommended
that the statement focus on larviciding in sub-Saharan
Africa in particular, and that it makes clear that larvicid-
ing is not generally recommended in rural areas. It was
stressed that the statement needed to balance a range of
views in an area where evidence is limited. The MPAC
recommended that the draft statement should be revised
based on the above points with the help of a few MPAC
members, before being formally issued together with a
brief preamble on the rationale for an interim statement
and its restriction to Africa. They also recommended
that the details of the interim position statement be pre-
sented and discussed at the next ALMA meeting.
The MPAC called for a more substantive review of
malaria vector control at their next meeting in Septem-
ber, including discussing the potential role of a malaria
vector control TEG that could reflect the field's diversity
and review evidence on LSM and other interventions to
facilitate optimal choices of interventions within an inte-
grated approach to malaria vector control and insecticide
resistance management.
Classification of countries for elimination
WHO-GMP presented an overview of the criteria it uses
for the classification of countries by elimination phase,
and the progress of countries since 2007 [15]. WHO
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is implemented in the worst affected malaria-endemic
part of its national territory. The classification, which has
been published in the World Malaria Report since 2008,
distinguishes the three distinct programme phases of con-
trol, elimination and prevention of reintroduction, and
the transition phase of pre-elimination. Control-phase
countries that are implementing projects aimed at achiev-
ing localized “malaria-free zones” (e.g. Hainan in China or
Khartoum in Sudan) have also been listed in past editions
of the World Malaria Report. The primary questions to
the MPAC were: (a) should WHO-GMP continue to
categorize countries by the type of malaria programme
that is implemented in the worst affected malaria-endemic
part of the country, and (b) are the current qualitative
classification criteria adequate.
The MPAC was broadly in favour of continuing with
a simplified classification that is useful for countries
and the global malaria community to monitor progress
towards elimination goals. Regional and country repre-
sentatives appreciated the value of the WHO classifica-
tion to help mobilize national resources and maintain
momentum while also considering the economic impli-
cations regarding tourism and, in some cases, Global
Fund funding. The MPAC pointed out that the country-
level classification does not sufficiently capture the di-
versity of malaria control and elimination efforts within
countries [4].
The MPAC recommended that WHO-GMP should
develop an adaptation of the current classification by in-
cluding programmatic as well as epidemiological deter-
minants of country progress towards elimination for
consideration at its next meeting. In addition, WHO-
GMP should consider adding a country malaria risk de-
scription like the ones currently published in WHO’s
International Travel and Health country pages [16] to
the individual country profiles in the World Malaria Re-
port. It was agreed that WHO-GMP will develop a pro-
posal for a revised classification, together with draft
standard operating procedures (SOP) on the certifica-
tion of achievement of elimination, for presentation to
the MPAC at its next meeting in September 2012.
Estimating malaria cases and deaths
WHO-GMP presented its current methods for estimat-
ing the number of malaria cases and deaths, and com-
pared these methods with those being used by other
groups also involved in malaria burden estimation [17].
The wide uncertainty in all estimation methods, which is
exacerbated by the often unknown and variable quality
of the input data, in particular the lack of specificity of
verbal autopsies, was highlighted. WHO-GMP works
with a range of partners in the development of its esti-
mates; however, there is still no global consensus on thebest methods for malaria burden estimation given
current data limitations. While it is desirable to achieve
such a consensus, there also needs to be a major focus
on improving diagnostic testing, surveillance, and vital
registration such that the burden of malaria can be more
directly measured and the information used to manage
programmes. Because of these issues, WHO–GMP pro-
posed to MPAC the establishment of an ERG to examine
approaches to burden estimation with a view to identify-
ing procedures that: (a) provide robust burden estimates
around which there is consensus; (b) are open and trans-
parent; (c) can be readily updated, e.g. changes in
programme coverage; and (d) can be applied by endemic
countries.
The MPAC strongly endorsed the creation of such an
ERG to provide an initial report back to them by the
next meeting in September 2012. Given the complex
methodological discussion needed, MPAC recommended
that the ToR for the ERG will need to: (a) ensure that a
diversity of voices are heard; (b) focus less on past dis-
crepancies and more on a way forward to standardize
and validate methods that allow for consistent reporting
of trends; (c) address how to improve the quality of the
input data through improved malaria surveillance; and
(d) focus on the best interests of WHO member states
and the global malaria community as a whole. WHO-
GMP, in close consultation with the MPAC, will quickly
draft the ToR and convene an ERG with clear independ-
ence and a reporting line to the MPAC in order to make
consensus-based and evidence-informed recommenda-
tions. Membership will need to balance malariologists
and non-malariologists so that there is a sufficient depth
and breadth of expertise.
Seasonal malaria chemoprevention (SMC)
The co-chair of the TEG on malaria chemotherapy pre-
sented its recommendation on SMC using amodiaquine-
sulphadoxine-pyrimethamine (AQ-SP) [18-20]. There is
strong evidence for high efficacy (approximately 80% re-
duction in malaria cases) and cost-effectiveness in areas
of the Sahel sub-region with marked seasonality in mal-
aria transmission (defined as 60% of cases occurring
within four months).
Subsequent discussion by the MPAC addressed ques-
tions about the choice of anti-malarial drug and appro-
priate pharmacovigilance measures, the practicalities of
implementation in countries with artemisinin-based
combination therapy (ACT) containing either AQ or SP
as first-line treatment, and the potential age displace-
ment of morbidity as a consequence of the delay in the
acquisition of immunity due to the intervention. Con-
sensus was reached on: (a) the completeness of the lit-
erature review – the general conclusion was that using
the word “chemoprophylaxis”, which is a similar term to
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come of the recommendation, but that it needs to be
clearer why earlier studies of seasonal chemoprophylaxis
were not included in the review; and (b) the effective-
ness of SMC with AQ-SP – the general conclusion was
that there is a window of opportunity related to the
current effectiveness of AQ-SP and that SMC should be
adopted soon, while operational experience and new evi-
dence will be regularly reviewed by the MPAC.
The MPAC recommended the adoption of SMC as a
new malaria control strategy pending minor changes to
the policy recommendation. There was strong consensus
on the need to rapidly finalize and disseminate the SMC
policy recommendation, ideally within two months of
the MPAC meeting.
Specific clarifications that will be made by the TEG and
WHO-GMP to the SMC recommendation before MPAC
endorsement include: (a) making the recommendation
flexible rather than prescriptive, such that countries have
latitude in how to implement this new intervention, and
are not required to change their first-line treatment; (b)
that methods for monitoring of effectiveness should be
developed immediately; and (c) clear language regarding
intervals of repeated dosing and the nature of areas and
settings suitable for implementation [21].
The MPAC recommended that the implementation
guide and relevant operational materials about SMC ex-
plicitly address the following issues: (a) the apparent para-
dox between the push for universal access to diagnostic
testing for suspected malaria and the new policy on SMC;
(b) the difference between SMC and other intermittent
interventions e.g. Intermittent Preventive Treatment in
infants (IPTi), explaining that SMC and IPTi should not
be deployed simultaneously in a given area; (c) that SMC
is not a replacement for existing malaria control strat-
egies, including vector control and access to prompt diag-
nostic testing and effective treatment; (d) an explanation
of the criteria for the literature review that provided the
evidence base for SMC; and (e) an explanation of the po-
tential age displacement of clinical malaria that may result
from the intervention.
The MPAC and WHO-GMP called on product develop-
ment partnerships to develop AQ-SP co-blistered combi-
nations meeting international quality standards for use in
SMC. In addition, new SMC studies should be promoted
and initiated to evaluate the safety and effectiveness of
combination therapies – different from the ACT currently
used for malaria treatment – that might be used in the fu-
ture for SMC in areas where AQ-SP is no longer suffi-
ciently effective.
Discussion
The MPAC discussed several potential topics for future
meetings, mainly: (a) the management of malarial andnon-malarial fevers; (b) prevention of malaria during preg-
nancy, including dose frequency of intermittent preventive
treatment (IPTp) with sulphadoxine-pyrimethamine and
if/when to stop IPTp in areas of low transmission; (c) a
global strategy for the control and elimination of P. vivax
malaria; (d) an update on the RTS,S malaria vaccine; and
(e) an update on the Affordable Medicines Facility for mal-
aria (AMFm), including the outcome of the independent
evaluation of this programme. The MPAC also recom-
mended the creation of an ERG on the use and safety of
primaquine as a gametocytocide for P. falciparum malaria,
which will report back to the MPAC at its next meeting in
September, as this is an urgent issue.
The MPAC strongly encouraged engagement with and
attendance by interested stakeholders at MPAC meet-
ings. In addition to open registration for MPAC meet-
ings, which will continue, and attendance by four
standing observers (Roll Back Malaria (RBM), the Glo-
bal Fund, UNICEF, Office of the UN Special Envoy for
malaria) and representatives of three rotating NMCPs,
WHO-GMP will continue to actively contact relevant
stakeholders in the global malaria community and invite
them to be observers for the next MPAC meeting in
September 2012. In addition, all six WHO Regional
Malaria Advisors will be invited to attend MPAC meet-
ings as members of the Secretariat.
Standing agenda items suggested by MPAC include a
brief review of ERGs and TEGs, and a review of any con-
ditional policy recommendations or interim position state-
ments, in case these need to be updated. In addition,
MPAC meetings, to take place every March and Septem-
ber, fit well with RBM Board meetings, which take place
every May and November. This will provide an additional
mechanism for recommendations from MPAC to be dis-
seminated to RBM partners and working groups, as well
to gather feedback from RBM partners and working
groups on priority issues and potential agenda items for
consideration by MPAC. Feedback on agenda items will
also be sought from WHO Regional Offices and NMCPs
by WHO-GMP.
The MPAC suggested making malaria policies and
guidelines more accessible and audience-targeted on the
WHO-GMP website, an improvement that is already
under consideration as part of a broader Knowledge
Management Strategy by WHO-GMP, which will be
shared with MPAC and other partners for input.
Conclusions
The inaugural MPAC meeting was well attended [22]
and feedback from participants and observers was very
positive. The meeting marked a transition period for
WHO-GMP and the global malaria community, from
having no current overarching advisory body for global
malaria policy setting, to a committee of experts that is
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process for malaria control and elimination. The MPAC
is still in the process of orienting itself to best serve the
needs of the global malaria community in responding to
a rapidly evolving landscape. As such, the format of
MPAC meetings and its feedback loops with other advis-
ory bodies and stakeholders is still taking shape, and will
evolve with time; WHO-GMP and the MPAC strongly
welcomed feedback, support, and suggestions for im-
provement to MPAC meetings from the global malaria
community.
Position statements and policy recommendations made
by the MPAC are approved by the WHO Director Gen-
eral, and will be formally issued and disseminated to
WHO member states by WHO-GMP. Conclusions and
recommendations from MPAC meetings (following the
format of this article) will be published in the Malaria
Journal as part of this series.
The next meeting of the MPAC will take place from 11
to 13 September 2012 in Geneva, Switzerland. Further in-
formation including the agenda and details on how to
register will be made available in July 2012 on the WHO-
GMP website for MPAC [1].
Endnotes
aThe complete set of all MPAC meeting-related docu-
ments including background papers and member declara-
tions of interest can be found online at http://www.who.
int/malaria/mpac/mpacmeetings/en/.
bThe WHO Malaria RDT Product Testing Programme
is a joint project of the WHO Special Programme for Re-
search and Training in Tropical Diseases (TDR), Founda-
tion for Innovative New Diagnostics (FIND), US Centers
for Disease Control and Prevention (CDC) and WHO-
GMP, in collaboration with a number of research institu-
tions and control programmes in malaria endemic and
non-endemic countries.
cIn product testing parasitized blood samples from
patients are diluted to ensure they consistently have the
same parasite density (and range of antigen concentra-
tions); however in the field, samples of parasitized blood
from patients are much more likely to have heteroge-
neous parasite densities – generally with a parasitaemia
higher than 200 parasites/μL.
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